Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952558 | 1.00 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL953323 | 1.00 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL30148056 | 1.00 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL9248648 | 0.86 | ALDH1A1 (0.62) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL3206832 | 0.86 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL10850388 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL112859 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12640200 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27722038 | 0.84 | ALDH1A1 (0.59) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL939536 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114106041-A | Process for synthesizing triphenylphosphine halogenated salt by solvent-free reaction method | 江苏宝众宝达药业股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-107428092-B | Additive manufacturing method using photomodulated free radical polymerization | 陶氏环球技术有限责任公司 | 2021-06-08 | — | — | CN | claimed |
| EP-3271155-B1 | METHOD OF ADDITIVE MANUFACTURING USING PHOTOREGULATED RADICAL POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-30 | — | — | EP | claimed |
| US-20180036942-A1 | METHOD OF ADDITIVE MANUFACTURING USING PHOTOREGULATED RADICAL POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC | 2018-02-08 | — | — | US | claimed |
| EP-3271155-A1 | METHOD OF ADDITIVE MANUFACTURING USING PHOTOREGULATED RADICAL POLYMERIZATION | Dow Global Technologies LLC (US) | 2018-01-24 | — | — | EP | claimed |
| US-20170240660-A1 | USING ORGANIC PHOTOREDOX CATALYSTS TO ACHIEVE METAL FREE PHOTOREGULATED CONTROLLED RADICAL POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC | 2017-08-24 | — | — | US | claimed |
| EP-3204434-A1 | USING ORGANIC PHOTOREDOX CATALYSTS TO ACHIEVE METAL FREE PHOTOREGULATED CONTROLLED RADICAL POLYMERIZATION | Dow Global Technologies Llc (US) | 2017-08-16 | — | — | EP | claimed |
| WO-2016057486-A1 | USING ORGANIC PHOTOREDOX CATALYSTS TO ACHIEVE METAL FREE PHOTOREGULATED CONTROLLED RADICAL POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-04-14 | — | — | WO | claimed |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117736134-A | Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases | 耶鲁大学 | 2024-03-22 | — | — | CN | disclosed |
| EP-4263526-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TREATMENT OF SKIN DISEASE | Pfizer Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-0061768-A1 | N-amido substituted dipeptides | USV PHARMACEUTICAL CORPORATION (US) | 1982-10-06 | — | — | EP | disclosed |
| US-4337354-A | BRAIN AND SPINAL CHORD DAMAGE | MERCK & CO., INC. (US) | 1982-06-29 | — | — | US | disclosed |
| US-4317922-A | [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives | MERCK & CO., INC. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4316043-A | ANTIEDEMIC AGENTS | MERCK & CO., INC. (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0027948-A1 | Tetrahydro-fluorene compounds, processes for their preparation and pharmaceutical compositions thereof | MERCK & CO. INC. (US) | 1981-05-06 | — | — | EP | disclosed |
| US-3970678-A | Organotin mercaptide process | CINCINNATI MILACRON CHEMICALS, INC. (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | ITK, BLK, BCKDK | ALDH1A1 412/4885TDP1 2058/4885MAPK1 1427/4885 |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | ALDH1A1 2756/4885TDP1 3547/4885MAPK1 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.